International journal of nanomedicine · 2018
Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Xin, Jia Xiaoqian, Niu Hu
Аннотация
BACKGROUND: Multidrug resistance is responsible for the poor outcome in breast cancer therapy. Lapa is a novel therapeutic agent that generates ROS through the catalysis of the NAD(P) H:quinone oxidoreductase-1 (NQO1) enzyme which significantly facilitate the intracellular accumulation of the co-delivered DOX to overcome MDR in cancer cells.
PURPOSE: Herein, in our study, nanostructured lipid carrier (NLC) co-delivering β-lapachone (Lapa) and doxorubicin (DOX) was developed (LDNLC) with the aim to overcome the multidrug resistance (MDR) in breast cancer therapy.
PATIENTS AND METHODS: Lapa and DOX were loaded into NLC to prepare LDNLC using melted ultrasonic dispersion method.
RESULTS: The well designed LDNLC was nanoscaled particles that exhibited preferable stability in physiological environment. In vitro cell experiments on MCF-7 ADR cells showed increased DOX retention as compared to DOX mono-delivery NLC (DNLC). In vivo anti-cancer assays on MCF-7 ADR tumor bearing mice model also revealed significantly enhanced efficacy of LDNLC than mono-delivery NLCs (DNLC and LNLC).
CONCLUSION: LDNLC might be a promising platform for effective breast cancer therapy.
PURPOSE: Herein, in our study, nanostructured lipid carrier (NLC) co-delivering β-lapachone (Lapa) and doxorubicin (DOX) was developed (LDNLC) with the aim to overcome the multidrug resistance (MDR) in breast cancer therapy.
PATIENTS AND METHODS: Lapa and DOX were loaded into NLC to prepare LDNLC using melted ultrasonic dispersion method.
RESULTS: The well designed LDNLC was nanoscaled particles that exhibited preferable stability in physiological environment. In vitro cell experiments on MCF-7 ADR cells showed increased DOX retention as compared to DOX mono-delivery NLC (DNLC). In vivo anti-cancer assays on MCF-7 ADR tumor bearing mice model also revealed significantly enhanced efficacy of LDNLC than mono-delivery NLCs (DNLC and LNLC).
CONCLUSION: LDNLC might be a promising platform for effective breast cancer therapy.
Предметные рубрики MeSH
Adenosine TriphosphateAnimalsAntineoplastic AgentsBreast NeoplasmsCell DeathCell SurvivalColloidsDoxorubicinDrug CarriersDrug LiberationDrug Resistance, MultipleDrug Resistance, NeoplasmFemaleHemolysisHumansLipidsMCF-7 CellsMice, Inbred BALB CMice, NudeNanostructuresNaphthoquinonesParticle SizeRabbitsStatic ElectricityTissue DistributionTumor Burden